Lanza E, Coda C, Ramella S, Ciambellotti E, Moro G, Cartia G L
Minerva Med. 1986 Sep 15;77(34-35):1521-5.
CEA, TPA, GICA and Ferritin were assayed in 700 cancer patients (230 assays in 181 breast cancers, 75 in 57 lung cancers, 114 in 70 cervico-facial neoplasms, 131 in 95 uterovaginal tumours, 444 in 225 colorectal tumours, 106 in 72 gastric cancers). Groups were divided into stages and the results of all possible associations were assessed. Only the most significant are reported. Among combinations of 2 markers the combined assay of CEA and TPA offers the best response as diagnostic potential (expressed as percentage positivity) in all neoplasm groups as well as a good correlation with the evolution of the disease.
对700例癌症患者检测了癌胚抗原(CEA)、组织多肽抗原(TPA)、免疫金标法(GICA)和铁蛋白。其中包括181例乳腺癌检测230次、57例肺癌检测75次、70例头颈部肿瘤检测114次、95例子宫阴道肿瘤检测131次、225例结直肠肿瘤检测444次、72例胃癌检测106次。将患者分组并评估所有可能组合的检测结果。仅报告最显著的结果。在两种标志物的组合中,CEA和TPA联合检测在所有肿瘤组中作为诊断潜力(以阳性百分比表示)具有最佳响应,并且与疾病进展具有良好的相关性。